Clough Capital Partners’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $900K | Sell |
14,350
-124,090
| -90% | -$9.93M | 0.09% | 89 |
|
|
2025
Q4 | $13.2M | Buy |
+138,440
| New | +$13.6M | 1.17% | 32 |
|
|
2025
Q3 | – | Sell |
-6,000
| Closed | -$644K | – | 114 |
|
|
2025
Q2 | $644K | Sell |
6,000
-3,000
| -33% | -$304K | 0.06% | 98 |
|
|
2025
Q1 | $908K | Hold |
9,000
| – | – | 0.11% | 82 |
|
|
2024
Q4 | $804K | Hold |
9,000
| – | – | 0.09% | 94 |
|
|
2024
Q3 | $754K | Hold |
9,000
| – | – | 0.08% | 105 |
|
|
2024
Q2 | $693K | Hold |
9,000
| – | – | 0.08% | 101 |
|
|
2024
Q1 | $616K | Hold |
9,000
| – | – | 0.07% | 95 |
|
|
2023
Q4 | $520K | Hold |
9,000
| – | – | 0.06% | 133 |
|
|
2023
Q3 | $475K | Sell |
9,000
-62,860
| -87% | -$3.3M | 0.05% | 134 |
|
|
2023
Q2 | $3.89M | Sell |
71,860
-85,517
| -54% | -$4.47M | 0.39% | 76 |
|
|
2023
Q1 | $7.87M | Sell |
157,377
-199,850
| -56% | -$9.42M | 0.85% | 40 |
|
|
2022
Q4 | $16.5M | Buy |
357,227
+252,827
| +242% | +$10.9M | 1.68% | 14 |
|
|
2022
Q3 | $4.04M | Sell |
104,400
-105,700
| -50% | -$4.24M | 0.43% | 38 |
|
|
2022
Q2 | $7.83M | Buy |
210,100
+121,900
| +138% | +$4.96M | 0.97% | 33 |
|
|
2022
Q1 | $3.91M | Buy |
+88,200
| New | +$3.82M | 0.3% | 72 |
|
|
2020
Q1 | – | Sell |
-258,946
| Closed | -$11.7M | – | 131 |
|
|
2019
Q4 | $11.7M | Buy |
258,946
+10,286
| +4% | +$430K | 1% | 40 |
|
|
2019
Q3 | $10.1M | Buy |
248,660
+163,990
| +194% | +$6.95M | 0.84% | 34 |
|
|
2019
Q2 | $3.64M | Sell |
84,670
-191,830
| -69% | -$7.38M | 0.36% | 72 |
|
|
2019
Q1 | $10.6M | Buy |
276,500
+65,500
| +31% | +$2.5M | 0.93% | 36 |
|
|
2018
Q4 | $7.46M | Buy |
211,000
+115,700
| +121% | +$4.2M | 0.88% | 41 |
|
|
2018
Q3 | $3.67M | Hold |
95,300
| – | – | 0.35% | 65 |
|
|
2018
Q2 | $3.12M | Hold |
95,300
| – | – | 0.28% | 73 |
|
|
2018
Q1 | $2.6M | Hold |
95,300
| – | – | 0.25% | 79 |
|
|
2017
Q4 | $2.36M | Sell |
95,300
-162,100
| -63% | -$4.47M | 0.2% | 75 |
|
|
2017
Q3 | $7.51M | Hold |
257,400
| – | – | 0.5% | 54 |
|
|
2017
Q2 | $7.13M | Hold |
257,400
| – | – | 0.5% | 52 |
|
|
2017
Q1 | $6.4M | Sell |
257,400
-23,825
| -8% | -$579K | 0.41% | 66 |
|
|
2016
Q4 | $6.08M | Buy |
281,225
+257,700
| +1,095% | +$5.62M | 0.4% | 68 |
|
|
2016
Q3 | $560K | Sell |
23,525
-160,925
| -87% | -$3.84M | 0.03% | 149 |
|
|
2016
Q2 | $4.31M | Buy |
184,450
+8,500
| +5% | +$184K | 0.23% | 110 |
|
|
2016
Q1 | $3.31M | Buy |
+175,950
| New | +$3.09M | 0.16% | 123 |
|
|
2013
Q4 | – | Sell |
-582,300
| Closed | -$6.84M | – | 204 |
|
|
2013
Q3 | $6.84M | Sell |
582,300
-362,300
| -38% | -$3.92M | 0.21% | 137 |
|
|
2013
Q2 | $8.76M | Buy |
+944,600
| New | +$8.01M | 0.29% | 113 |
|
Other funds holding BSX
VCM
VPM
Clough Capital Partners's BSX Position: Q1 2026 in Review
Clough Capital Partners reduced its Boston Scientific (BSX) stake by 90% in Q1 2026, selling an estimated $9.93M and leaving 14,350 shares worth $900K. The position accounts for 0.09% of the portfolio, ranked #89.
Clough Capital Partners first reported a position in BSX in Q2 2013 and has held it in 34 quarters since. The position peaked at $16.5M in Q4 2022. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Clough Capital Partners held 14,350 shares of Boston Scientific worth $900K as of Q1 2026.
- Clough Capital Partners sold 124,090 Boston Scientific shares in Q1 2026, an estimated $9.93M.
- Boston Scientific made up 0.09% of Clough Capital Partners's portfolio in Q1 2026, its #89 holding.
- Clough Capital Partners first reported a position in Boston Scientific in Q2 2013 and has held it in 34 quarters since.
- Clough Capital Partners's Boston Scientific position peaked at $16.5M in Q4 2022.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Clough Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.